ArticleTurkish journal of medical sciences2025
Turkish translation, validity, and reliability of the European organization for research and treatment of cancer quality of life-high dose chemotherapy29 in patients undergone hematopoietic stem cell transplantation.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Our aim was to investigate psychometric properties of the Turkish version of the European organization for research and treatment of cancer quality of life-high dose chemotherapy29 (EORTC QLQ-HDC29) in patients treated with hematopoietic stem cell transplantation (HSCT). Materials and methods: Patients between the ages of 18 and 65 years and undergone HSCT were included. The European organization for research and treatment of cancer quality of life questionnaire-cancer30 the Eastern cooperative oncology group performance score, and the functional assessment of cancer therapy-bone marrow transplant were used to determine convergent validity. Reliability was assessed through the calculation of Cronbach's alpha and intra-class correlation coefficient (ICC) values. Results: Totally 151 patients were included. The convergent validity analysis between the EORTC QLQ-HDC29 and the other variables revealed significant, low to strong correlations (p < 0.05). The test-retest reliability of the questionnaire was excellent (ICC values ranged from 0.886 to 1.000). The internal consistency values were acceptable except for the "Worries/Anxiety" and "Inpatient Issues" scales (ranged from 0.175 to 0.985). Conclusion: The reliability and validity of Turkish version of the EORTC QLQ-HDC29 was feasible and acceptable in patients treated with HSCT. Further research is required to ascertain the psychometric properties of the EORTC QLQ-HD29.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.